RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Phathom Pharmaceuticals Stock

Phathom Pharmaceuticals Net Income 2024

Phathom Pharmaceuticals Net Income

-360.56 M USD

Ticker

PHAT

ISIN

US71722W1071

WKN

A2PT0F

In 2024, Phathom Pharmaceuticals's profit amounted to -360.56 M USD, a 78.86% increase from the -201.59 M USD profit recorded in the previous year.

The Phathom Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e75.37
2028e10.33
2027e-95.43
2026e-137.47
2025e-273.42
2024e-360.56
2023-201.59
2022-197.72
2021-143.88
2020-129.07
2019-255.13
2018-1.29

Phathom Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Phathom Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Phathom Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Phathom Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Phathom Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Phathom Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Phathom Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Phathom Pharmaceuticals’s growth potential.

Phathom Pharmaceuticals Revenue, EBIT and net profit per share

DatePhathom Pharmaceuticals RevenuePhathom Pharmaceuticals EBITPhathom Pharmaceuticals Net Income
2029e816.89 M undefined0 undefined75.37 M undefined
2028e720.16 M undefined216.7 M undefined10.33 M undefined
2027e523.71 M undefined68.26 M undefined-95.43 M undefined
2026e387.45 M undefined-133.07 M undefined-137.47 M undefined
2025e177.12 M undefined-242.05 M undefined-273.42 M undefined
2024e45.09 M undefined-286.83 M undefined-360.56 M undefined
2023682,000 undefined-167.31 M undefined-201.59 M undefined
20220 undefined-172.44 M undefined-197.72 M undefined
20210 undefined-135.08 M undefined-143.88 M undefined
20200 undefined-125.67 M undefined-129.07 M undefined
20190 undefined-106.22 M undefined-255.13 M undefined
20180 undefined-1.23 M undefined-1.29 M undefined

Phathom Pharmaceuticals stock margins

The Phathom Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Phathom Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Phathom Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Phathom Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Phathom Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Phathom Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Phathom Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Phathom Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Phathom Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Phathom Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Phathom Pharmaceuticals Margin History

Phathom Pharmaceuticals Gross marginPhathom Pharmaceuticals Profit marginPhathom Pharmaceuticals EBIT marginPhathom Pharmaceuticals Profit margin
2029e75.51 %0 %9.23 %
2028e75.51 %30.09 %1.43 %
2027e75.51 %13.03 %-18.22 %
2026e75.51 %-34.34 %-35.48 %
2025e75.51 %-136.66 %-154.37 %
2024e75.51 %-636.08 %-799.57 %
202375.51 %-24,532.55 %-29,558.95 %
202275.51 %0 %0 %
202175.51 %0 %0 %
202075.51 %0 %0 %
201975.51 %0 %0 %
201875.51 %0 %0 %

Phathom Pharmaceuticals Aktienanalyse

What does Phathom Pharmaceuticals do?

Phathom Pharmaceuticals Inc. is a pharmaceutical company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. The company is headquartered in Florham Park, New Jersey and was founded in 2016. The company's business model is focused on utilizing its innovative technology and expertise in the medical treatment of gastrointestinal disorders to improve the lives of patients. It works closely with doctors and hospitals to ensure that its products are developed to the highest standards. The company is divided into different business segments to enable optimal patient care and market penetration. The key business segments are: 1. Gastroesophageal reflux disease Phathom has developed a medication called Vonoprazan for the treatment of gastroesophageal reflux disease. This common condition occurs when stomach acid flows back into the esophagus, causing pain, inflammation, and heartburn. The medication blocks the production of stomach acid, thus helping to relieve the symptoms of reflux disease. 2. Helicobacter pylori infection The company has also developed a medication called Ryzodeg for the treatment of Helicobacter pylori infection. This infection, caused by a type of bacteria, can lead to stomach ulcers and other gastrointestinal disorders. Ryzodeg is a combination of an antimicrobial substance and a proton pump inhibitor, which together are more effective than individual medications. 3. Eosinophilic esophagitis Phathom is currently developing a medication for the treatment of eosinophilic esophagitis (EoE), an allergic inflammation of the esophagus that can cause difficulty swallowing, pain, and diarrhea. The medication is currently in the clinical development phase and could soon be on the market. Phathom Pharmaceuticals was founded by a group of experienced executives from the pharmaceutical and biotech industry, including CEO Dr. Azmi Nabulsi and COO Dr. Tuan Ha-Ngoc. Both have extensive experience in the development and marketing of medications and contribute their expertise to the company's management. The company also specializes in partnerships with other pharmaceutical companies and clinical research institutions to advance its research and development. For example, the company has entered into a strategic partnership with Takeda Pharmaceuticals to advance the development and marketing of Vonoprazan. Phathom Pharmaceuticals is a promising company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. With its innovative technology and experienced management, the company is expected to continue growing in the future and help improve the health of patients around the world. Phathom Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Phathom Pharmaceuticals's Profit Margins

The profit margins of Phathom Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Phathom Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Phathom Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Phathom Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Phathom Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Phathom Pharmaceuticals stock

How much profit has Phathom Pharmaceuticals made this year?

Phathom Pharmaceuticals has made -360.56 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 78.86% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Phathom Pharmaceuticals publish its earnings?

Phathom Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Phathom Pharmaceuticals?

The profits of Phathom Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Phathom Pharmaceuticals?

You can learn more about the earnings of Phathom Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Phathom Pharmaceuticals pay?

Over the past 12 months, Phathom Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phathom Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phathom Pharmaceuticals?

The current dividend yield of Phathom Pharmaceuticals is .

When does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phathom Pharmaceuticals?

Phathom Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phathom Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phathom Pharmaceuticals located?

Phathom Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phathom Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phathom Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Phathom Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Phathom Pharmaceuticals in the year 2023?

In the year 2023, Phathom Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phathom Pharmaceuticals pay out the dividend?

The dividends of Phathom Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Phathom Pharmaceuticals

Our stock analysis for Phathom Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phathom Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.